[{"id":"91d2096c-32dd-4272-9b5e-ad8cf92f638c","acronym":"iCARE4Lynch","url":"https://clinicaltrials.gov/study/NCT07472686","created_at":"2026-03-28T01:39:52.485Z","updated_at":"2026-03-28T01:39:52.485Z","phase":"","brief_title":"Small Bowel Capsule Endoscopy in Lynch Syndrome","source_id_and_acronym":"NCT07472686 - iCARE4Lynch","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • EPCAM"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/16/2025","start_date":" 06/16/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2026-03-16"},{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"1f7645ce-b871-4582-a76b-ca5622eeebeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05419011","created_at":"2022-06-15T16:54:47.107Z","updated_at":"2025-02-25T13:41:05.612Z","phase":"Phase 2","brief_title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","source_id_and_acronym":"NCT05419011","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-21"},{"id":"60bce1a2-b876-426c-a77f-15b4b5b443a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03805919","created_at":"2021-01-18T18:48:39.011Z","updated_at":"2025-02-25T15:34:18.012Z","phase":"","brief_title":"Men at High Genetic Risk for Prostate Cancer","source_id_and_acronym":"NCT03805919","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 01/01/2029","primary_completion_date":" 01/01/2029","study_txt":" Completion: 01/01/2039","study_completion_date":" 01/01/2039","last_update_posted":"2025-02-10"},{"id":"f4760edc-575b-4a03-b52a-92d92e44dfde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02371135","created_at":"2021-01-18T11:17:42.064Z","updated_at":"2025-02-25T16:51:29.235Z","phase":"","brief_title":"Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes","source_id_and_acronym":"NCT02371135","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"43ad41ea-ee88-438e-ba85-a91a571ee263","acronym":"","url":"https://clinicaltrials.gov/study/NCT03996239","created_at":"2022-01-29T17:44:32.508Z","updated_at":"2024-07-02T16:34:25.688Z","phase":"","brief_title":"Researching the Effect of Aerobic Exercise on Cancer","source_id_and_acronym":"NCT03996239","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-14"},{"id":"ef502e78-36b6-4881-b791-586dbda2fa9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379999","created_at":"2021-01-18T21:09:15.617Z","updated_at":"2024-07-02T16:34:26.352Z","phase":"Phase 1","brief_title":"Atorvastatin ± Aspirin in Lynch Syndrome Syndrome","source_id_and_acronym":"NCT04379999","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM • CASP3","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"ca62bd95-d966-4ef1-89f6-bb6e6f3f98af","acronym":"","url":"https://clinicaltrials.gov/study/NCT06432296","created_at":"2024-05-29T20:34:47.293Z","updated_at":"2024-07-02T16:35:00.222Z","phase":"Phase 3","brief_title":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","source_id_and_acronym":"NCT06432296","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" EPCAM","pipe":"","alterations":" ","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 03/20/2024","start_date":" 03/20/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-05-29"},{"id":"99825282-13d0-4537-9611-5aeeb9d9b074","acronym":"PCEDP","url":"https://clinicaltrials.gov/study/NCT02206360","created_at":"2021-01-18T10:19:50.126Z","updated_at":"2024-07-02T16:35:01.200Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Program","source_id_and_acronym":"NCT02206360 - PCEDP","lead_sponsor":"White Plains Hospital","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-24"},{"id":"c675e0ca-7f1a-4e3c-8775-d10e0e747837","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358563","created_at":"2024-05-03T20:26:05.283Z","updated_at":"2025-02-25T16:31:15.404Z","phase":"Phase 1","brief_title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","source_id_and_acronym":"NCT03358563","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" AR • EPCAM","pipe":"","alterations":" ","tags":["AR • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • bicalutamide • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 09/02/2022","study_completion_date":" 09/02/2022","last_update_posted":"2024-05-03"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"5f16282f-b255-4864-95a6-951ea5963c93","acronym":"","url":"https://clinicaltrials.gov/study/NCT05818865","created_at":"2023-04-19T19:07:03.089Z","updated_at":"2024-07-02T16:35:12.902Z","phase":"","brief_title":"\"Principle Test\" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.","source_id_and_acronym":"NCT05818865","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" EPCAM • VIM","pipe":" | ","alterations":" CA9 expression","tags":["EPCAM • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 03/22/2022","primary_completion_date":" 03/22/2022","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-26"},{"id":"107dd190-b738-4816-b39c-d6828e427b79","acronym":"PancreasScan","url":"https://clinicaltrials.gov/study/NCT05006131","created_at":"2021-08-16T17:54:43.106Z","updated_at":"2024-07-02T16:35:13.981Z","phase":"","brief_title":"Pancreatic Cancer Screening for At-risk Individuals","source_id_and_acronym":"NCT05006131 - PancreasScan","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 03/10/2027","primary_completion_date":" 03/10/2027","study_txt":" Completion: 03/10/2028","study_completion_date":" 03/10/2028","last_update_posted":"2024-03-19"},{"id":"50564d19-a3cf-4bcc-8943-3dff05053f5c","acronym":"IGNITE-TX","url":"https://clinicaltrials.gov/study/NCT05677048","created_at":"2023-01-10T15:59:23.994Z","updated_at":"2024-07-02T16:35:17.318Z","phase":"","brief_title":"Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing \u0026 Treatment) Intervention","source_id_and_acronym":"NCT05677048 - IGNITE-TX","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" BRCA1 mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-02-28"},{"id":"942c232f-7333-4f3f-b161-29ff99678077","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122896","created_at":"2023-11-08T22:13:14.798Z","updated_at":"2024-07-02T16:35:17.268Z","phase":"Phase 1","brief_title":"Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","source_id_and_acronym":"NCT06122896","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 11/21/2023","start_date":" 11/21/2023","primary_txt":" Primary completion: 10/31/2040","primary_completion_date":" 10/31/2040","study_txt":" Completion: 10/31/2041","study_completion_date":" 10/31/2041","last_update_posted":"2024-02-28"},{"id":"5d0f978b-61f7-4e60-b450-92e2db41b6c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04257045","created_at":"2021-01-18T20:41:29.194Z","updated_at":"2024-07-02T16:35:19.446Z","phase":"","brief_title":"Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives","source_id_and_acronym":"NCT04257045","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • EPCAM • BARD1 • DICER1","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • EPCAM • BARD1 • DICER1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 08/21/2019","start_date":" 08/21/2019","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-02-14"},{"id":"bfb4df12-9ec3-4d7d-b560-7b4ce0e231e4","acronym":"CORAL","url":"https://clinicaltrials.gov/study/NCT05410977","created_at":"2022-06-08T11:58:19.127Z","updated_at":"2024-07-02T16:35:23.099Z","phase":"","brief_title":"Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study","source_id_and_acronym":"NCT05410977 - CORAL","lead_sponsor":"Mayo Clinic","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 03/30/2022","start_date":" 03/30/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-18"},{"id":"30822141-25e9-4fd4-a1b7-75e0617cd56c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03495674","created_at":"2021-01-18T17:12:44.870Z","updated_at":"2024-07-02T16:35:24.381Z","phase":"","brief_title":"Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome","source_id_and_acronym":"NCT03495674","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 04/04/2018","start_date":" 04/04/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 01/02/2024","study_completion_date":" 01/02/2024","last_update_posted":"2024-01-05"},{"id":"52833369-8f35-4158-93c0-4c396a7d8604","acronym":"GENERATE","url":"https://clinicaltrials.gov/study/NCT03762590","created_at":"2021-01-18T18:29:19.005Z","updated_at":"2024-07-02T16:35:25.717Z","phase":"","brief_title":"GENetic Education Risk Assessment and TEsting Study","source_id_and_acronym":"NCT03762590 - GENERATE","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation","tags":["TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 12/12/2022","primary_completion_date":" 12/12/2022","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-12-20"},{"id":"a179cee7-5ed4-48d5-8b29-279b434cdab8","acronym":"PROGRESS","url":"https://clinicaltrials.gov/study/NCT05129605","created_at":"2021-11-22T14:53:36.295Z","updated_at":"2024-07-02T16:35:26.710Z","phase":"","brief_title":"Prostate Cancer Genetic Risk Evaluation and Screening Study","source_id_and_acronym":"NCT05129605 - PROGRESS","lead_sponsor":"Massachusetts General Hospital","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • GEN1 • HOXB13","pipe":" | ","alterations":" CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • GEN1 • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2023-12-08"},{"id":"24101395-efd5-45f7-b263-ca1e7f90853b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02915445","created_at":"2021-01-18T14:18:46.620Z","updated_at":"2024-07-02T16:35:28.369Z","phase":"Phase 1","brief_title":"EpCAM CAR-T for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT02915445","lead_sponsor":"Sichuan University","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-22"},{"id":"fc21c219-c013-4138-9fe8-07a9c22cead0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013216","created_at":"2021-08-19T14:52:56.438Z","updated_at":"2024-07-02T16:35:38.156Z","phase":"Phase 1","brief_title":"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","source_id_and_acronym":"NCT05013216","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1","pipe":" | ","alterations":" KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation","tags":["KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-04"},{"id":"745d414a-1381-4871-ac56-b4ca7a316273","acronym":"","url":"https://clinicaltrials.gov/study/NCT05421520","created_at":"2023-08-24T18:10:53.231Z","updated_at":"2024-07-02T16:35:39.065Z","phase":"","brief_title":"Effectiveness of an Ai-based Endoscopic Ultrasound Navigation System in the Training of Endoscopic Ultrasonics","source_id_and_acronym":"NCT05421520","lead_sponsor":"Renmin Hospital of Wuhan University","biomarkers":" BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" BRCA1 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • PALB2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/08/2023","start_date":" 10/08/2023","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2023-08-24"},{"id":"2daa2951-8e63-44d7-b2e1-6c92b1f411c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04247503","created_at":"2021-01-18T20:38:41.861Z","updated_at":"2024-07-02T16:35:41.473Z","phase":"","brief_title":"Cohort Study of Pancreatic Cancer Risk","source_id_and_acronym":"NCT04247503","lead_sponsor":"Mayo Clinic","biomarkers":" TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation","tags":["TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 12/11/2019","start_date":" 12/11/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"}]